Metastatic Brain Tumor

7

Review clinical trials related to Metastatic Brain Tumor. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study of Olutasidenib and Temozolomide in HGG

The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.

Participants needed: 60
Trial details
Phase: Phase 2Age: 12-39Biological sex: AllType: InterventionalSponsor: Rigel PharmaceuticalsUpdated: Jun 12, 2026Locations: 20
Eligibility criteria

Stratum A: Patients with localized, intracranial, non-pontine, and non-thalamic... [+23]

Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entere... [+26]

Status: Recruiting

Targeted Pediatric High-Grade Glioma Therapy

The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical trial based on the genetic alterations identified in their tumor.

Participants needed: 350
Trial details
Age: 12-39Biological sex: AllType: ObservationalSponsor: Nationwide Children's HospitalUpdated: Jun 10, 2026Locations: 21
Eligibility criteria

Age: Patients must be ≥12 months and ≤39 years of age at the time of enrollment... [+21]

Status: Recruiting

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target or 2) ribociclib and temozolomide to treat pediatric and young adult patients newly diagnosed with diffuse hemispheric glioma (DHG), H3G34-mutant. The main question the study aims to answer is whether the combinations of ribociclib and everolimus or ribociclib and temozolomide can prolong the life of patients diagnosed with HGG/DIPG or DHG H3G34-mutant.

Participants needed: 120
Trial details
Phase: Phase 2Age: 12-39Biological sex: AllType: InterventionalSponsor: Nationwide Children's HospitalUpdated: May 29, 2026Locations: 20
Eligibility criteria

Stratum A: Patients with localized, intracranial, non-pontine, and non-thalamic... [+35]

Pregnant or Breast-Feeding Pregnant or breast-feeding women will not be entered... [+22]

Status: Not yet recruiting

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

The goal of this study is to determine the efficacy of the study drugs tovorafenib to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (MAPK) that this drug targets. The main question the study aims to answer is whether tovorafenib can prolong the life of patients diagnosed with HGG, including DIPG.

Participants needed: 79
Trial details
Phase: Phase 2Age: 12-39Biological sex: AllType: InterventionalSponsor: Nationwide Children's HospitalUpdated: Apr 8, 2026
Eligibility criteria

Patient must have previously enrolled on TarGeT-SCR. [+24]

Pregnancy or breastfeeding. [+6]

Status: Recruiting

Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).

Participants needed: 119
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Mar 6, 2026Locations: 1
Eligibility criteria

Age ≥ 18 years [+9]

Pregnant or breastfeeding women [+2]

Status: Recruiting

F-Tryptophan PET/CT in Human Cancers

Imaging procedures such as 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.

Participants needed: 24
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Barbara Ann Karmanos Cancer InstituteUpdated: Jan 23, 2026Locations: 1
Eligibility criteria

Age ≥18 years. [+13]

Patients who are pregnant or lactating are excluded. [+5]

Status: Recruiting

Assessment of Eloquent Function in Brain Tumor Patients

Purpose of the study: AIM 1: Prospectively collect pre-operative \[functional magnetic resonance imaging (fMRI), diffusion tensor imaging (DTI), magnetoencephalography (MEG)\] and intra-operative mapping data in patients with intra-axial brain tumors to assess how well each modality predicts the location of eloquent brain function. In addition, each modality will be compared with the other. AIM 2: Assess reorganization of eloquent brain function and plasticity in patients with intra-axial brain tumors. This will be accomplished by prospectively collecting post-operative mapping studies and neuropsychological tests to compare them to prior mapping studies as stated above.

Participants needed: 75
Trial details
Age: 19+Biological sex: AllType: ObservationalSponsor: University of NebraskaUpdated: Jan 13, 2026Locations: 1
Eligibility criteria

19 years and older [+4]

Any contraindication to MRI (i.e. implanted devices) [+6]